DxS Expand their Portfolio of Cancer Mutation Products, with the Launch of a PI3K Mutation Detection Kit

DxS has announced the addition of a PI3K Mutation Detection Kit to their portfolio of oncogene mutation products.

PI3K is a biomarker assessed during the evaluation of the tyrosine kinase inhibitors targeting the EGFR pathway. The PI3K-AKT pathway is activated in a variety of tumour types resulting in cell growth and proliferation.

DxS’ PI3K Mutation Test Kit will detect 4 somatic mutations in exons 9 and 20 of the PIK3CA oncogene which are frequently found in a number of different cancers including up to 40% of breast cancer. The presence of these mutations may influence the response to targeted therapies and prognosis, and screening for PI3K mutations using the DxS kit will aid researchers in determining these correlations.

Using the real-time PCR technology Scorpions®, DxS has claimed the development of a highly sensitive and selective test to detect mutations at very low levels that can be performed in less than three hours. The assay is able to detect 1% of mutation in a background of wild-type genomic DNA and its unrivalled selectivity means that it highlights mutations often missed by sequencing methods.